Articles tagged with Bone Cancer
Researchers found that retreatment with decitabine resulted in 45% of patients achieving any response, with some experiencing partial or complete remission. The median overall survival was 28 months, and continued outpatient maintenance treatment is being studied for its benefits.
A study of 11,481 childhood cancer survivors found that 20% had physical performance limitations compared to 12% of their siblings. Rehabilitation programs improved survival rates after heart attacks by reducing subsequent heart attacks by 17%.
A randomized trial of 900 patients with breast or prostate cancer found that a shorter course of radiation therapy was as effective as the standard treatment in providing pain relief. The study also showed less acute toxicity and re-treatment rates in patients who received a single dose of 8 Gy radiation.
A national study of cancer patients who underwent bone marrow transplantation reveals long-term quality of life issues persist for decades. Cancer survivors report lingering sleep, sexual problems, pain, cognitive decline, and poor physical well-being compared to healthy peers.
A five-year-old girl with Ewing’s sarcoma had her leg turned into a 'knee' using rotationplasty to remove the diseased portion of bone. The procedure has improved limb-sparing surgery outcomes for children with cancer above the knee, with better function and durability.
A new study found that hormone deprivation therapy is less effective for younger men with higher grade tumors, suggesting it needs further investigation as an alternative treatment for localized prostate cancer. The study also revealed a higher risk of bone fractures in men on hormone therapy due to osteoporosis.
Researchers created an experimental model that limited radiation to the site of cancer in mice, demonstrating a localized single radiation dose decreases painful behavior and increases limb use. Treated mice had significantly less bone destruction and tumor burden, leading to greater pain relief.
Researchers have discovered a new bone-targeted mTOR inhibitor that decreases both tumor proliferation and bone breakdown for the treatment of bone cancer. Additionally, studies have shown efficacy of radioimmunotherapy using radiolabeled HerceptinTM in combination with gemcitabine in treating intraperitoneal disease.
A Danish study found that individuals exposed to contaminated poliovirus vaccine had no increased risk of cancer compared to those not exposed. The findings contradict previous laboratory and epidemiologic evidence suggesting a link between SV40 contamination and human cancer.
The Mayo Clinic study found that the risk of progression from MGUS to multiple myeloma or related cancers is approximately one percent per year, with larger M-protein levels increasing the risk. Patients with very small protein levels had a 14% progression rate at 20 years, while those with high levels had a 60% progression rate.
A Mayo Clinic study has confirmed the effectiveness of samarium as a treatment option for osteosarcoma, with 24 of 30 patients experiencing a good to excellent response. The radioactive drug targets tumors in the bone, killing off cancer cells and reducing side effects associated with chemotherapy.
Researchers found that 71% of women experienced ovarian function loss and rapid bone loss after six months of chemotherapy, leading to significant bone loss by the end of one year. The study suggests that earlier intervention with calcium, vitamin D, weight-bearing exercise, and counseling may help prevent bone loss in these patients.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
A clinical trial testing tin-117m DTPA, a nuclear medicine compound, may provide non-sedating pain relief and treatment for advanced-stage bone cancer. The therapy has shown promising results in easing pain for over 75% of patients, with relief lasting up to a year.
A study by Memorial Sloan-Kettering Cancer Center found that 77% of adult AML patients who received a T-cell depleted bone marrow transplant were cancer-free after 6 years. The treatment limits graft-versus-host disease risk and leukemic recurrence.